Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Obese Patients With Untreated Dyslipidemias (RIO-Lipids)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00029835
Recruitment Status : Completed
First Posted : January 24, 2002
Last Update Posted : April 20, 2009
Sponsor:
Information provided by:
Sanofi

Brief Summary:
To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia

Condition or disease Intervention/treatment Phase
Obesity Dyslipidemia Drug: Rimonabant (SR141716) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1033 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study of Weight-Reducing Effect and Safety in Obese Patients With Untreated Dyslipidemias
Study Start Date : September 2001
Actual Primary Completion Date : November 2003
Actual Study Completion Date : November 2003



Primary Outcome Measures :
  1. Change from baseline in body weight at 1 year.

Secondary Outcome Measures :
  1. Metabolic parameters


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • BMI must be greater than 27 and less than 40
  • Patients with untreated dyslipidemia
  • Stable weight (variation of less than 5 kg within 3 months prior to screening visit)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00029835


  Show 35 Study Locations
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: ICD CSD Sanofi

Publications of Results:
Layout table for additonal information
Responsible Party: ICD Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00029835     History of Changes
Other Study ID Numbers: EFC4735
First Posted: January 24, 2002    Key Record Dates
Last Update Posted: April 20, 2009
Last Verified: April 2009

Keywords provided by Sanofi:
Obesity

Additional relevant MeSH terms:
Layout table for MeSH terms
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Rimonabant
Anti-Obesity Agents
Cannabinoid Receptor Antagonists
Cannabinoid Receptor Modulators
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs